Member Info for Computer909

So now less than 50% of the placing price, surely we could expect some sort of update on the P3 trial and general operations towards the end of the year?

For LTH the timing of this placing is good news, raise cash when the SP is high means you have to dilute the share by a smaller proportion, For all that jumped in here last week expecting the Covid vaccine makers to throw away their months of trial data and to restart with a Nuvec packaged product were just ill-informed. This is a longer term investment that will be tremendous in the medium to long term, H2 2021 is where the action will be.

I don't think i have ever heard any news from ODX with regards to actual sales or orders, (apart from the small UK-RTC order that was announced by Abingdon and we assumed our proportion). We only hear about capacity ramp up, but surely to carry on increasing capacity needs to be backed by some orders, the problem being is although Abingdon received a larger order for "components" it looks like our contract with the UK-RTC is based on number of tests so we don't see a share of that pie until someone says deliver so many tests.

We really need an update on the progress of P3 trial enrolment before the end of the year, thats the only thing that will stabilise the SP, a major move from the market will only take place when/if we get full adoption from health authorities around the world for the preferential usage of SNG001 for covid treatment. Before SNG001 becomes the go to treatment we are all holding hoping to get our money back, after that happens we should look to recover previous highs. IMO

“Our immediate priority is to progress SNG001 as a therapeutic for COVID-19 and, as such, our COPD programme will remain paused.“

Surely with vaccinations approval having a fundamental impact on the company’s priority we would expect some sort of update for the market ,whilst we all understand how hard the company must be working, responding to such news is all part of running a listed company

Absolutely classic AIM response to good news, down 7%

Where is the link to this leak, lets all see it?

@Russky, I'm referring current sentiment rather than the need for a placing, When i took up the placing offer in July i hoped we would have moved on by now, just saying if i was in the same situation now would i have taken up the offer?, With the fundamentals probably would, but it does make you question your research and sanity.

Hovering around the placing price wont bode well for any future expansion plans, no one wants to take up a placing offer if the BOD can’t actually move the company forward with the cash injection,

"The Company signed a material transfer agreement ("MTA") with Mologic in June of this year providing access to raw materials and know-how to manufacture their lateral flow antigen test. This test determines the concentration of COVID-19 (SARS-CoV-2) antigens in a saliva or swab extract sample to identify an individual with an infection. Mologic is currently evaluating a prototype in a number of healthcare settings and the results to date look promising. If this continues, then by the end of November, Omega would look to commence technical transfer of the test prior to commencing manufacturing."

So the end of November for concrete news one way or the other, anything has to be better than this death by a thousand cuts.

Mologic Tech Transfer is the only news that can prop us up until the new year, The 15th December travel quarantine testing market has to be a target now

What price ODX without any COVID testing ?

The problem being we hear about ramp up in capacity, but don't see any sales news, all starting to be a little Jam tomorrow, which i never thought i'd say regarding ODX, With the lack of large Institutional investors the BOD need to give a care to the SP, especially when their main funding route would be an share placing, we could be back to the placing value with another day like this.

I think someone needs to tell Colin Christmas is cancelled, this is becoming shambolic, so much promise, so little delivery.

Clear the sentiment is that the other tests could go the way of the ELISA test, zero take up.

Will now likely miss any tender possibility for the UK from the antigen moonshot demand (Government more than happy to keep buying innova tests, why wouldn't they if thats all the can get)

Didn't think we would see the 40s again and still on a downward spiral

Avacta were down until about 11:00AM, and someone discovered the use of the word Affimers in a government testing document, now they are up 4%, just shows the AIM casino in action.

We could get news of Mologic Tech Transfer and a slice of the £912M testing contract, Could get news of a one-for-one order to match the AZ vaccine rollout for the Antibody test, could get news of CD4 test purchases for WHO backed programmes, Could get news of massive orders for food intolerance tests in china.

Or we could get news that CK has had his thumb up his arse for the last three months and has spu**ed all our cash against the wall and is sat in a villa in the Caribbean sipping ****tails.

Which do you think is a more likely scenario?

Lets remember that the AZ Vaccine test data only covers people that were confirmed covid "untouched", ie that have never had the virus before, no data is yet available to cover this section of the community (quite a large proportion by the time we get to full scale rollout), so at the moment they will need to confirm the absence of antibodies before dishing out the jab, otherwise they don't know the impact, So more need for Antibody tests

I don't expect there will be an RNS on progress any time soon, the most you can hope for is to pick up some sound bites in the webinar or via social media, We all knew (Well I hope you did) what you have invested in, before positive vaccine news therapeutics were the holy grail, now they are somewhat of an also ran. I'm sure SNG is worth more than its current SP if it can get good results on P3 trial for Covid and more importantly COPD. Investing here initially at 40p was a dream, but after averaging up its now just a punt. But lets not get into the situation where we are demanding updates via RNS daily, expect an update January, until then hold tight or sell which ever you need to do.

@Patience001, I agree SNG have unfortunately missed the boat for large scale Covid use, as the vaccine rollout proceeds there will be much less of an appetite to rapidly adopt new treatments, so the million dollar question therefore becomes what is the true worth of SNG if we are marketing as COPD / Asthma treatment, and what P3 trial will be needed for those approvals and how long will that take?

@Tomvisual, you cant tender for contracts when you dont have s product